WallStreetZenWallStreetZen

NASDAQ: EGRX
Eagle Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their EGRX stock forecasts and price targets.

Forecast return on equity

Is EGRX forecast to generate an efficient return?

Forecast return on assets

Is EGRX forecast to generate an efficient return on assets?

EGRX revenue forecast

What is EGRX's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$224.8M-12.72%
EGRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EGRX revenue growth forecast

How is EGRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
-12.72%
Industry
13.58%
Market
12.87%
EGRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EGRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EGRX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
EGRX$4.24N/AN/A
SCYX$1.47N/AN/A
RMTI$1.51$9.00+496.03%Buy
TKNO$1.70N/AN/A
RGC$5.35N/AN/A
View Top Pharmaceutical Stocks

Eagle Pharmaceuticals Stock Forecast FAQ

What is EGRX's revenue growth forecast for 2024-2024?

(NASDAQ: EGRX) Eagle Pharmaceuticals's forecast annual revenue growth rate of -12.72% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 13.58%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.87%.

Eagle Pharmaceuticals's revenue in 2024 is $257,551,000.

In 2024, EGRX is forecast to generate $2,919,471,081 in revenue, with the lowest revenue forecast at $2,919,471,081 and the highest revenue forecast at $2,919,471,081.

If you're new to stock investing, here's how to buy Eagle Pharmaceuticals stock.

What is EGRX's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: EGRX) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 13.3%.

What is EGRX's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: EGRX) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.